Enhancement of NAD+-dependent SIRT1 deacetylase activity by methylselenocysteine resets the circadian clock in carcinogen-treated mammary epithelial cells

Oncotarget

Volumn 6, Issue 40, 2015, Pages 42879-42891

  Fang, Mingzhu ^a,b,c,d,e   Guo, Wei Ren ^a   Park, Youngil ^f   Kang, Hwan Goo ^f   Zarbl, Helmut ^a,b,c,d,e  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d The State University of New Jersey   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^f Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

Author keywords

Circadian clock; Methylselenocysteine; N methyl N nitrosourea; Period 2; SIRT1

Indexed keywords

CARCINOGEN; HISTONE H3; MESSENGER RNA; METHYLNITROSOUREA; METHYLSELENOCYSTEINE; NICOTINAMIDE ADENINE DINUCLEOTIDE; ORGANOSELENIUM DERIVATIVE; PER2 PROTEIN; PROTEIN H3K9; PROTEIN INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SIRTUIN 1; TRANSCRIPTION FACTOR ARNTL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; SELENOCYSTEINE; SELENOMETHYLSELENOCYSTEINE; SIRT1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST EPITHELIUM CELL; CELL PROTECTION; CIRCADIAN RHYTHM; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUCIFERASE ASSAY; MAMMARY GLAND; MOLECULAR MECHANICS; NONHUMAN; PROMOTER REGION; PROTEIN ACETYLATION; PROTEIN DEPLETION; RAT; ANALOGS AND DERIVATIVES; ANIMAL; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; EPITHELIUM CELL; FISCHER 344 RAT; GENETIC EPIGENESIS; GENETIC TRANSFECTION; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; UDDER;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; CHROMATIN IMMUNOPRECIPITATION; CIRCADIAN CLOCKS; EPIGENESIS, GENETIC; EPITHELIAL CELLS; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; METHYLNITROSOUREA; NAD; RATS; RATS, INBRED F344; REAL-TIME POLYMERASE CHAIN REACTION; SELENOCYSTEINE; SIRTUIN 1; TRANSFECTION;

EID: 84952333904     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6002     Document Type: Article

References (52)

1. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 2003; 3:350-361.
2. Chen-Goodspeed M, Lee CC. Tumor suppression and circadian function. J Biol Rhythms. 2007; 22:291-298.
3. Balsalobre A. Clock genes in mammalian peripheral tissues. Cell Tissue Res. 2002; 309:193-199.
4. Mackey SR. Biological rhythms workshop IA: Molecular Basis of Rhythms Generation In: Stillman B SD, Grodzicker T, ed. Cold Spring Harbor Symposia on Quantitative Biology (Cold Spring Harbor: Cold Spring Harbor Laboratory Press). 2007; pp. 7-19.
5. Rana S, Mahmood S. Circadian rhythm and its role in malignancy. J Circadian Rhythms. 2010; 8:3.
6. Chen Z, Odstrcil EA, Tu BP, McKnight SL. Restriction of DNA replication to the reductive phase of the metabolic cycle protects genome integrity. Science. 2007; 316:1916-1919.
7. Destici E, Oklejewicz M, Nijman R, Tamanini F, Van Der Horst GT. Impact of the circadian clock on in vitro genotoxic risk assessment assays. Mutation Res. 2009; 680:87-94.
8. Oklejewicz M, Destici E, Tamanini F, Hut RA, Janssens R, Van Der Horst GT. Phase resetting of the mammalian circadian clock by DNA damage. Curr Biol. 2008; 18:286-291.
9. Haus EL, Smolensky MH. Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Medicine Reviews. 2013; 17:273-284.
10. Fu L, Kettner NM. The circadian clock in cancer development and therapy. Prog Mol Biol Transi Sci. 2013; 119:221-282.
11. Fu A, Leaderer D, Zheng T, Hoffman AE, Stevens RG, Zhu Y. Genetic and epigenetic associations of circadian gene TIMELESS and breast cancer risk. Mol Carcinogenesis. 2012; 51:923-929.
12. Mao Y, Fu A, Hoffman AE, Jacobs DI, Jin M, Chen K, Zhu Y. The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications. Tumour Biol. 2015; 36:3533-3539.
13. Fang MZ, Zhang X, Zarbl H. Methylselenocysteine resets the rhythmic expression of circadian and growth-regulatory genes disrupted by nitrosomethylurea in vivo. Cancer Prev Res (Phila). 2010; 3:640-652.
14. Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene. 2007; 26:7916-7920.
15. Zhang X, Zarbl H. Chemopreventive doses of methylselenocysteine alter circadian rhythm in rat mammary tissue. Cancer Prev Res (Philadelphia, Pa.). 2008; 1:119-127.
16. Jackson MI, Combs GF, Jr. Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care. 2008; 11:718-726.
17. El-Bayoumy K, Upadhyaya P, Sohn OS, Rosa JG, Fiala ES. Synthesis and excretion profile of 1, 4-[14C] phenylenebis(methylene)selenocyanate in the rat. Carcinogenesis. 1998; 19:1603-1607.
18. Hu Y, Spengler ML, Kuropatwinski KK, Comas-Soberats M, Jackson M, Chernov MV, Gleiberman AS, Fedtsova N, Rustum YM, Gudkov AV, Antoch MP. Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1. Oncotarget. 2011; 2:1279-1290.
19. Cao S, Durrani FA, Toth K, Rustum YM. Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models. British Journal of Cancer. 2014; 110:1733-1743.
20. Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis. 1999; 20:1657-1666.
21. De Silva V, Woznichak MM, Burns KL, Grant KB, May SW. Selenium redox cycling in the protective effects of organoselenides against oxidant-induced DNA damage. Journal of the American Chemical Society. 2004; 126:2409-2413.
22. Wu M, Kang MM, Schoene NW, Cheng WH. Selenium compounds activate early barriers of tumorigenesis. J Biol Chem. 285:12055-12062.
23. Dziaman T, Huzarski T, Gackowski D, Rozalski R, Siomek A, Szpila A, Guz J, Lubinski J, Wasowicz W, Roszkowski K, Olinski R. Selenium supplementation reduced oxidative DNA damage in adnexectomized BRCA1 mutations carriers. Cancer Epidemiol Biomarkers Prev. 2009; 18:2923-2928.
24. Youn BW, Fiala ES, Sohn OS. Mechanisms of organoselenium compounds in chemoprevention: effects on transcription factor-DNA binding. Nutr Cancer. 2001; 40:28-33.
25. Smith ML, Lancia JK, Mercer TI, Ip C. Selenium compounds regulate p53 by common and distinctive mechanisms. Anticancer Res. 2004; 24:1401-1408.
26. Xiang N, Zhao R, Song G, Zhong W. Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells. Carcinogenesis. 2008; 29:2175-2181.
27. Fiala ES, Staretz ME, Pandya GA, El-Bayoumy K, Hamilton SR. Inhibition of DNA cytosine methyltransferase by chemopreventive selenium compounds, determined by an improved assay for DNA cytosine methyltransferase and DNA cytosine methylation. Carcinogenesis. 1998; 19:597-604.
28. Ip C, Lisk DJ, Thompson HJ. Selenium-enriched garlic inhibits the early stage but not the late stage of mammary carcinogenesis. Carcinogenesis. 1996; 17:1979-1982.
29. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther. 2009; 8:1409-1420.
30. Crosio C, Cermakian N, Allis CD, Sassone-Corsi P. Light induces chromatin modification in cells of the mammalian circadian clock. Nat Neurosci. 2000; 3:1241-1247.
31. Etchegaray JP, Lee C, Wade PA, Reppert SM. Rhythmic histone acetylation underlies transcription in the mammalian circadian clock. Nature. 2003; 421:177-182.
32. Doi M, Hirayama J, Sassone-Corsi P. Circadian regulator CLOCK is a histone acetyltransferase. Cell. 2006; 125:497-508.
33. Nakahata Y, Kaluzova M, Grimaldi B, Sahar S, Hirayama J, Chen D, Guarente LP, Sassone-Corsi P. The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell. 2008; 134:329-340.
34. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama. 2009; 301:39-51.
35. Storch KF, Lipan O, Leykin I, Viswanathan N, Davis FC, Wong WH, Weitz CJ. Extensive and divergent circadian gene expression in liver and heart. Nature. 2002; 417:78-83.
36. Ueda HR, Chen W, Adachi A, Wakamatsu H, Hayashi S, Takasugi T, Nagano M, Nakahama K, Suzuki Y, Sugano S, Iino M, Shigeyoshi Y, Hashimoto S. A transcription factor response element for gene expression during circadian night. Nature. 2002; 418:534-539.
37. Wijnen H, Young MW. Interplay of circadian clocks and metabolic rhythms. Annu Rev Genet. 2006; 40:409-448.
38. Braidy N, Guillemin GJ, Mansour H, Chan-Ling T, Poljak A, Grant R. Age related changes in NAD+ metabolism oxidative stress and Sirt1 activity in wistar rats. PloS one. 2011; 6:e19194.
39. Virag L. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies. Curr Vasc Pharmacol. 2005; 3:209-214.
40. Haimovich B, Calvano J, Haimovich AD, Calvano SE, Coyle SM, Lowry SF. In vivo endotoxin synchronizes and suppresses clock gene expression in human peripheral blood leukocytes. Crit Care Med. 2010; 38:751-758.
41. Belden WJ, Dunlap JC. SIRT1 is a circadian deacetylase for core clock components. Cell. 2008; 134:212-214.
42. Asher G, Gatfield D, Stratmann M, Reinke H, Dibner C, Kreppel F, Mostoslavsky R, Alt FW, Schibler U. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell. 2008; 134:317-328.
43. Chen Z, Yoo SH, Takahashi JS. Small molecule modifiers of circadian clocks. Cellular and molecular life sciences: CMLS. 2013; 70:2985-2998.
44. Sladek M, Polidarova L, Novakova M, Parkanova D, Sumova A. Early chronotype and tissue-specific alterations of circadian clock function in spontaneously hypertensive rats. PLoS One. 2012; 7:e46951.
45. Roseboom PH, Namboodiri MA, Zimonjic DB, Popescu NC, Rodriguez IR, Gastel JA, Klein DC. Natural melatonin 'knockdown' in C57BL/6J mice: rare mechanism truncates serotonin N-acetyltransferase. Brain Res Mol Brain Res. 1998; 63:189-197.
46. Muhlbauer E, Gross E, Labucay K, Wolgast S, Peschke E. Loss of melatonin signalling and its impact on circadian rhythms in mouse organs regulating blood glucose. Eur J Pharmacol. 2009; 606:61-71.
47. Elangovan S, Ramachandran S, Venkatesan N, Ananth S, Gnana-Prakasam JP, Martin PM, Browning DD, Schoenlein PV, Prasad PD, Ganapathy V, Thangaraju M. SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor alpha in breast cancer. Cancer Res. 2011; 71:6654-6664.
48. Hayashida S, Arimoto A, Kuramoto Y, Kozako T, Honda S, Shimeno H, Soeda S. Fasting promotes the expression of SIRT1, an NAD+-dependent protein deacetylase, via activation of PPARalpha in mice. Mol Cell Biochem. 2010; 339:285-292.
49. Koltai E, Szabo Z, Atalay M, Boldogh I, Naito H, Goto S, Nyakas C, Radak Z. Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats. Mech Ageing Dev. 2010; 131:21-28.
50. Marton O, Koltai E, Nyakas C, Bakonyi T, Zenteno-Savin T, Kumagai S, Goto S, Radak Z. Aging and exercise affect the level of protein acetylation and SIRT1 activity in cerebellum of male rats. Biogerontology. 2010; 11:679-686.
51. Yang T, Sauve AA. NAD metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicity. AAPS J. 2006; 8:E632-643.
52. Chen Z, Yoo SH, Park YS, Kim KH, Wei S, Buhr E, Ye ZY, Pan HL, Takahashi JS. Identification of diverse modulators of central and peripheral circadian clocks by high-throughput chemical screening. Proc Natl Acad Sci U S A. 2012; 109:101-106.